Skip to main content
Medical information Clinical review pending

Genetic Testing

HBOC Extended Panel Hereditary Breast and Ovarian Cancer 32 Genes

The HBOC Extended Panel Hereditary Breast and Ovarian Cancer 32 Genes test assesses your genetic risk for breast and ovarian cancers by analysing 32 key genes. It's recommended for individuals with a significant family history of these cancers.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Peripheral blood collected in an EDTA Vacutainer tube (2ml).
Results
Approximately 4-5 weeks. Confirm with the laboratory before booking.
Preparation
No specific preparation is required for this blood test. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the HBOC Extended Panel Hereditary Breast and Ovarian Cancer 32 Genes test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Personal history of breast cancer diagnosed at a young age (e.g., under 50).
  • ✓Family history of breast cancer (especially multiple relatives, early-onset cases, or bilateral cancer).
  • ✓Family history of ovarian cancer.
  • ✓Family history of other related cancers (e.g., pancreatic, prostate, melanoma).
  • ✓Individuals of Ashkenazi Jewish descent.
  • ✓Individuals seeking genetic counseling for hereditary cancer risk assessment.
02

In plain language

What this test helps you understand

Identifies individuals with an increased genetic risk for hereditary breast and ovarian cancer, guiding personalized risk management strategies, surveillance, and potential preventive interventions.
The HBOC Extended Panel Hereditary Breast and Ovarian Cancer 32 Genes test is a comprehensive genetic assessment designed to evaluate your risk of developing breast and ovarian cancers. This test is particularly relevant for individuals with a family history of these cancers, as it helps identify specific genetic mutations that can significantly increase susceptibility. Understanding your genetic predisposition allows for proactive health management, including enhanced screening and preventive strategies.

This test analyzes 32 genes known to be associated with hereditary breast and ovarian cancer syndromes. It specifically looks for mutations in genes like BRCA1 and BRCA2, as well as others linked to increased cancer risk. The detailed analysis provides valuable information for making informed decisions about your health and potential interventions.

Understanding your genetic risk can empower you and your healthcare provider to develop a personalized health plan. Results can also inform family members about potential risks they may face.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific preparation is required for this blood test. Confirm with the laboratory before booking.
SamplePeripheral blood collected in an EDTA Vacutainer tube (2ml).
MethodologyNext-Generation Sequencing (NGS) or similar molecular techniques are used to analyze the DNA sequence of the specified genes.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes 32 specific genes associated with HBOC risk. It does not detect all possible genetic mutations that could increase cancer risk. A negative result does not completely rule out a genetic predisposition. Results should be interpreted in the context of personal and family history by a qualified healthcare professional.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test analyzes 32 genes associated with an increased risk of hereditary breast and ovarian cancer, including BRCA1 and BRCA2.
Individuals with a personal or family history of breast or ovarian cancer, especially if diagnosed at a young age or if multiple family members are affected, should discuss this test with their doctor.
A positive result indicates a mutation was found, suggesting an increased risk. A negative result means no mutations were detected in the genes tested. Results require interpretation by a healthcare professional.
Yes, a prescription from a qualified healthcare provider is required before testing.
A blood sample is required for this test.
Results are typically available within 4-5 weeks. Confirm with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp